Psychopharmacologic Drugs : Affective Disorders
OLIGI1 “Ligilin capsule” 300 mg/cap
OLILI1 “Lilitin tablet” 300 mg/tab
適應症：
OLIGI1：躁病、預防躁鬱病。
OLILI1：預防及治療躁狂、躁鬱病。
Usual dose:
Bipolar disorder, manic episode:
Adult ( > 12 yrs): 1800 mg/day in 2-3 divided doses; desired serum lithium levels 1.0-1.5 mEq/L; maintenance, 900-1200 mg/day in 2-3 divided doses; desired serum lithium levels 0.6-1.2 mEq/L.
Contraindication:
Lactation, severe debilitation, dehydration, or sodium depletion; significant cardiovascular disease, renal impairment.
Precaution:
Discontinue lithium at least one week before initiating electroconvulsive therapy (ECT) and withhold lithium for several days after completing ECT.
Adverse effect:
Common: abnormal ecg, reversible flattening, isoelectricity or inversion of t-waves, diarrhea, nausea (mild), vomiting, may be signs of toxicity, xerostomia, muscle irritability, muscle weakness, eeg abnormality, diffuse slowing, widening of frequency spectrum, potentiation and disorganization of background rhythm, fine tremor, hyperreflexia, deep tendon, somnolence, visual field scotoma, transient, albuminuria, glycosuria, oliguria, polyuria.
Serious: bradyarrhythmia (severe), cardiac dysrhythmia, hypotension, sinus node dysfunction, ataxia, coma, pseudotumor cerebri, increased intracranial pressure and papilledema, seizure, epileptiform, blurred vis, tinnitus, may be signs of serious toxicity, giddiness, polyuria, dilute, may be a sign of serious toxicity.